MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The p53 tumor suppressor plays a key role in maintaining genomic stability and protection against malignant transformation. MDM2 and MDMX are both p53-binding proteins that regulate p53 stability and activity. Recent development of the MDM2 inhibitor Nutlin 3 has greatly facilitated functional analysis of MDM2-p53 binding. We found that although MDMX is homologous to MDM2 and binds to the same region on p53 N terminus, Nutlin does not disrupt p53-MDMX interaction. The ability of Nutlin to activate p53 is compromised in tumor cells overexpressing MDMX. Combination of Nutlin with MDMX siRNA resulted in synergistic activation of p53 and growth arrest. These results suggest that MDMX is also a valid target for p53 activation in tumor cells. Development of novel compounds that are MDMX-specific or optimized for dual-inhibition of MDM2 and MDMX are necessary to achieve full activation of p53 in tumor cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The IC50s reported in this study are consistent with previous reports showing that MDM2 amplified cancer cell lines (e.g. liposarcoma and osteosarcoma lines) are more sensitive to RG7112 or Nutlin-3 [25–28].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [28]
In the citing paper
“Although nutlin 3a and MI-219 robustly activate p53 in cancer cells with overexpressed MDM2, they do not consistently elicit p53-dependent effects in cancer cells that overexpress MDMX99–102.”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [101]
Citations
Cites
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
MDMX: a novel p53‐binding protein with some functional properties of MDM2.
Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648
Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., & Lozano, G. (2001) · Nature Genetics · doi:10.1038/ng714 · Cited by 517
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53
Linares, L. K., Hengstermann, A., Ciechanover, A., Müller, S., & Scheffner, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2030930100 · Cited by 361
MDM2 interacts with MDMX through their RING finger domains
Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., & Ohtsubo, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00254-9 · Cited by 324
Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., de Graaf, P., Francoz, S., Gasparini, P., Gobbi, A., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5835-5843.2004 · Cited by 310
MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting
Bond, G., Hu, W., & Levine, A. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 308
Stabilization of the MDM2 Oncoprotein by Interaction with the Structurally Related MDMX Protein
Sharp, D. A., Kratowicz, S. A., Sank, M. J., & George, D. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.53.38189 · Cited by 286
Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics
Vassilev, L. T. (2004) · Cell Cycle · doi:10.4161/cc.3.4.801 · Cited by 271
Mutual Dependence of MDM2 and MDMX in Their Functional Inactivation of p53
Gu, J., Kawai, H., Nie, L., Kitao, H., Wiederschain, D., Jochemsen, A. G., Parant, J., Lozano, G., & Yuan, Z.-M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200150200 · Cited by 265
Research works printed but not linked: 2
- Ramos, 2001, Cancer Res., 61, 1839
- Bottger, 1996, Oncogene, 13, 2141
Cited by
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
Self-citationShangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Coping with stress: multiple ways to activate p53
Horn, H. F., & Vousden, K. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210263 · Cited by 522
Translating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381
“It has emerged that targeting MDM2 alone is not sufficient therapeutically and that simultaneous targeting of the homolog MDM4 may be needed for maximal efficacy”
BackgroundTargeting the MDM2-p53 Interaction for Cancer Therapy
Shangary, S., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 366
Clinical Overview of MDM2/X-Targeted Therapies
Burgess, A., Chia, K. M., Haupt, S., Thomas, D., Haupt, Y., & Lim, E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00007 · Cited by 315
The Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 296
A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
Bernal, F., Wade, M., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 285
MDM2 and MDM4: p53 regulators as targets in anticancer therapy
Toledo, F., & Wahl, G. M. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.022 · Cited by 261
Efficient p53 Activation and Apoptosis by Simultaneous Disruption of Binding to MDM2 and MDMX
Hu, B., Gilkes, D. M., & Chen, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1140 · Cited by 213
Self-citationIdentification and Characterization of the First Small Molecule Inhibitor of MDMX
Reed, D., Shen, Y., Shelat, A. A., Arnold, L. A., Ferreira, A. M., Zhu, F., Mills, N., Smithson, D. C., Regni, C. A., Bashford, D., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.056747 · Cited by 198
Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 194
Phan, J., Li, Z., Kasprzak, A., Li, B., Sebti, S., Guida, W., Schönbrunn, E., & Chen, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073056 · Cited by 173
Self-citationTargeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170
“Surprisingly, neither Nutlin nor MI-219 appreciably antagonizes the Mdmx/p53 interaction in cancer cell lines, and high Mdmx reduces apoptosis and/or cell cycle arrest induced by these drugs (24, 51, 68, 69).”
BackgroundThe Transactivation Domains of the p53 Protein
Raj, N., & Attardi, L. D. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026047 · Cited by 168
Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Shen, H., & G. Maki, C. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222603 · Cited by 147
The Structure‐Based Design of Mdm2/Mdmx–p53 Inhibitors Gets Serious
Popowicz, G. M., Dömling, A., & Holak, T. A. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201003863 · Cited by 163
Visualization and targeted disruption of protein interactions in living cells
Herce, H. D., Deng, W., Helma, J., Leonhardt, H., & Cardoso, M. C. (2013) · Nature Communications · doi:10.1038/ncomms3660 · Cited by 162
Reactivation of p53: from peptides to small molecules
Brown, C. J., Cheok, C. F., Verma, C. S., & Lane, D. P. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.004 · Cited by 149
Drugging the undruggable: Transcription therapy for cancer
Yan, C., & Higgins, P. J. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.11.002 · Cited by 120
Molecular Basis for the Inhibition of p53 by Mdmx
Popowicz, G. M., Czarna, A., Rothweiler, U., Szwagierczak, A., Krajewski, M., Weber, L., & Holak, T. A. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4740 · Cited by 130
Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3
LeBron, C., Chen, L., Gilkes, D. M., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601032 · Cited by 122
Self-citationPotential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A
Müller, C. R., Paulsen, E. B., Noordhuis, P., Pedeutour, F., Sæter, G., & Myklebost, O. (2007) · International Journal of Cancer · doi:10.1002/ijc.22643 · Cited by 119
Targeting prostate cancer based on signal transduction and cell cycle pathways
Lee, J. T., Lehmann, B. D., Terrian, D. M., Chappell, W. H., Stivala, F., Libra, M., Martelli, A. M., Steelman, L. S., & McCubrey, J. A. (2008) · Cell Cycle · doi:10.4161/cc.7.12.6166 · Cited by 118
A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Wang, H., Ma, X., Ren, S., Buolamwini, J. K., & Yan, C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0581 · Cited by 117
Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation
Wang, Y. V., Wade, M., Wong, E., Li, Y.-C., Rodewald, L. W., & Wahl, G. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701497104 · Cited by 116
Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
Patel, S., & Player, M. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802493366 · Cited by 99
High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx
Czarna, A., Popowicz, G. M., Pecak, A., Wolf, S., Dubin, G., & Holak, T. A. (2009) · Cell Cycle · doi:10.4161/cc.8.8.8185 · Cited by 98
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.003 · Cited by 106
MdmX is a substrate for the deubiquitinating enzyme USP2a
Allende-Vega, N., Sparks, A., Lane, D. P., & Saville, M. K. (2010) · Oncogene · doi:10.1038/onc.2009.330 · Cited by 100
Saddler, C., Ouillette, P., Kujawski, L., Shangary, S., Talpaz, M., Kaminski, M., Erba, H., Shedden, K., Wang, S., & Malek, S. N. (2008) · Blood · doi:10.1182/blood-2007-09-112698 · Cited by 96
MicroRNA-34a Modulates MDM4 Expression via a Target Site in the Open Reading Frame
Mandke, P., Wyatt, N., Fraser, J., Bates, B., Berberich, S. J., & Markey, M. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042034 · Cited by 90
Gupta, A., Bharadwaj, M., Kumar, A., & Mehrotra, R. (2016) · Topics in Current Chemistry · doi:10.1007/s41061-016-0089-0 · Cited by 99
Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation
Jiang, M., Pabla, N., Murphy, R. F., Yang, T., Yin, X.-M., Degenhardt, K., White, E., & Dong, Z. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606928200 · Cited by 97
Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies
Joseph, T. L., Madhumalar, A., Brown, C. J., Lane, D. P., & Verma, C. S. (2010) · Cell Cycle · doi:10.4161/cc.9.6.11067 · Cited by 86
Small-molecule inhibitors of MDM2 as new anticancer therapeutics
Dickens, M. P., Fitzgerald, R. P., & Fischer, P. M. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.003 · Cited by 97
Small molecule agents targeting the p53‐MDM2 pathway for cancer therapy
Wang, W., & Hu, Y. (2012) · Medicinal Research Reviews · doi:10.1002/med.20236 · Cited by 85
Targeting p53-MDM2-MDMX Loop for Cancer Therapy
Zhang, Q., Zeng, S. X., & Lu, H. (2014) · Subcellular Biochemistry · doi:10.1007/978-94-017-9211-0_16 · Cited by 83
Targeting MDM2 for novel molecular therapy: Beyond oncology
Wang, W., Qin, J., Rajaei, M., Li, X., Yu, X., Hunt, C., & Zhang, R. (2019) · Medicinal Research Reviews · doi:10.1002/med.21637 · Cited by 94
Long, J., Parkin, B., Ouillette, P., Bixby, D., Shedden, K., Erba, H., Wang, S., & Malek, S. N. (2010) · Blood · doi:10.1182/blood-2010-01-261628 · Cited by 85
Xia, M., Knezevic, D., Tovar, C., Huang, B., Heimbrook, D. C., & Vassilev, L. T. (2008) · Cell Cycle · doi:10.4161/cc.7.11.5929 · Cited by 75
McCormack, E., Haaland, I., Venås, G., Forthun, R. B., Huseby, S., Gausdal, G., Knappskog, S., Micklem, D., Lorens, J. B., Bruserud, Ø., et al. (2011) · Leukemia · doi:10.1038/leu.2011.315 · Cited by 88
Targeting apoptosis pathways in glioblastoma
Eisele, G., & Weller, M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.12.012 · Cited by 88
MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
Ohnstad, H. O., Paulsen, E. B., Noordhuis, P., Berg, M., Lothe, R. A., Vassilev, L. T., & Myklebost, O. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-211 · Cited by 77
β-Peptides with improved affinity for hDM2 and hDMX
Harker, E. A., Daniels, D. S., Guarracino, D. A., & Schepartz, A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.01.039 · Cited by 71
Duhamel, L. A., Ye, H., Halai, D., Idowu, B. D., Presneau, N., Tirabosco, R., & Flanagan, A. M. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.04023.x · Cited by 85
Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry
Li, C., Pazgier, M., Li, J., Li, C., Liu, M., Zou, G., Li, Z., Chen, J., Tarasov, S. G., Lu, W.-Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116814 · Cited by 79
Self-citationTabe, Y., Sebasigari, D., Jin, L., Rudelius, M., Davies-Hill, T., Miyake, K., Miida, T., Pittaluga, S., & Raffeld, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0399 · Cited by 83
DNA damage response to the Mdm2 inhibitor Nutlin-3
Verma, R., Rigatti, M. J., Belinsky, G. S., Godman, C. A., & Giardina, C. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.09.020 · Cited by 76
Spontaneous Tumorigenesis in Mice Overexpressing the p53-Negative Regulator Mdm4
Xiong, S., Pant, V., Suh, Y.-A., Van Pelt, C. S., Wang, Y., Valentin-Vega, Y. A., Post, S. M., & Lozano, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1457 · Cited by 82
Regulation of MDMX Expression by Mitogenic Signaling
Gilkes, D. M., Pan, Y., Coppola, D., Yeatman, T., Reuther, G. W., & Chen, J. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01633-07 · Cited by 82
Self-citationKallen, J., Goepfert, A., Blechschmidt, A., Izaac, A., Geiser, M., Tavares, G., Ramage, P., Furet, P., Masuya, K., & Lisztwan, J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809096200 · Cited by 71
Inhibition of p53 DNA Binding Function by the MDM2 Protein Acidic Domain
Cross, B., Chen, L., Cheng, Q., Li, B., Yuan, Z.-M., & Chen, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228981 · Cited by 70
Self-citationRegulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis
Carr, M. I., & Jones, S. N. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.11.75 · Cited by 80
Pechackova, S., Burdova, K., Benada, J., Kleiblova, P., Jenikova, G., & Macurek, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7363 · Cited by 75
Hároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 76
Singh, R. K., Iyappan, S., & Scheffner, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610879200 · Cited by 70
In Silico Improvement of β3-Peptide Inhibitors of p53•hDM2 and p53•hDMX
Michel, J., Harker, E. A., Tirado‐Rives, J., Jorgensen, W. L., & Schepartz, A. (2009) · Journal of the American Chemical Society · doi:10.1021/ja901478e · Cited by 74
Wild type p53 reactivation: From lab bench to clinic
Selivanova, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.049 · Cited by 65
Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_2 · Cited by 72
“Indeed, ectopic expression of MDMX and/or its downregulation by RNAi show that MDMX attenuates the p53 activation by selective MDM2 inhibitors and reduces the cellular activity of MDM2 inhibitors [50, 66, 75, 76].”
Backgroundp53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors
Li, B., Cheng, Q., Li, Z., & Chen, J. (2010) · Cell Cycle · doi:10.4161/cc.9.7.11255 · Cited by 64
Self-citationGenome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
Stolte, B., Iniguez, A. B., Dharia, N. V., Robichaud, A. L., Conway, A. S., Morgan, A. M., Alexe, G., Schauer, N. J., Liu, X., Bird, G. H., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171066 · Cited by 68
Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation
París, R., Henry, R. E., Stephens, S. J., McBryde, M., & Espinosa, J. M. (2008) · Cell Cycle · doi:10.4161/cc.6420 · Cited by 63
de Lange, J., Ly, L. V., Lodder, K., Vries, M. V., Teunisse, A. F. A. S., Jager, M. J., & Jochemsen, A. G. (2011) · Oncogene · doi:10.1038/onc.2011.309 · Cited by 68
Ensemble-based virtual screening reveals dual-inhibitors for the p53–MDM2/MDMX interactions
Barakat, K., Mane, J. Y., Friesen, D. E., & Tuszyński, J. A. (2009) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2009.12.003 · Cited by 68
Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)
Zak, K., Pecak, A., Rys, B., Wladyka, B., Dömling, A., Weber, L., Holak, T. A., & Dubin, G. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.765405 · Cited by 65
Zanjirband, M., Edmondson, R. J., & Lunec, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9499 · Cited by 63
A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications
Wang, M., & Attardi, L. D. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-025840 · Cited by 66
Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin‐3 in gastric cancer cells
Endo, S., Yamato, K., Hirai, S., Moriwaki, T., Fukuda, K., Suzuki, H., Abei, M., Nakagawa, I., & Hyodo, I. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01821.x · Cited by 66
Forte, E., & Luftig, M. A. (2009) · Journal of Virology · doi:10.1128/jvi.01681-08 · Cited by 65
MDMX contains an autoinhibitory sequence element
Bista, M., Petrovich, M., & Fersht, A. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317398110 · Cited by 57
Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
DeVine, T., & Dai, M. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180009 · Cited by 62
Structural and Functional Basis for Therapeutic Modulation of p53 Signaling
Bassett, E. A., Wang, W., Rastinejad, F., & El-Deiry, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1526 · Cited by 57
Wang, H., & Yan, C. (2011) · Neoplasia · doi:10.1593/neo.11438 · Cited by 58
Pirh2 RING‐finger E3 ubiquitin ligase: Its role in tumorigenesis and cancer therapy
Jung, Y.-S., Qian, Y., & Chen, X. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.03.052 · Cited by 57
Toufektchan, E., Lejour, V., Durand, R., Giri, N., Drašković, I., Bardot, B., Laplante, P., Jaber, S., Alter, B. P., Londoño‐Vallejo, A., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay3511 · Cited by 56
Tsvetkov, P., Reuven, N., Prives, C., & Shaul, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.040493 · Cited by 54
Phillips, A., Teunisse, A., Lam, S., Lodder, K., Darley, M., Emaduddin, M., Wolf, A., Richter, J., de Lange, J., Verlaan-de Vries, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.129726 · Cited by 55
Vaseva, A. V., Yallowitz, A. R., Marchenko, N. D., Xu, S., & Moll, U. M. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.39 · Cited by 55
Vara, B., Mayasundari, A., Tellis, J. C., Danneman, M. W., Arredondo, V., Davis, T. A., Min, J., Finch, K. E., Guy, R. K., & Johnston, J. N. (2014) · The Journal of Organic Chemistry · doi:10.1021/jo501003r · Cited by 54
Analysis of the MDM2 antagonist nutlin‐3 in human prostate cancer cells
Logan, I. R., McNeill, H. V., Cook, S., Lü, X., Lunec, J., & Robson, C. N. (2007) · The Prostate · doi:10.1002/pros.20568 · Cited by 54
Collections of Simultaneously Altered Genes as Biomarkers of Cancer Cell Drug Response
Masica, D. L., & Karchin, R. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3122 · Cited by 48
Qi, D.-L., & Cobrinik, D. E. (2016) · Oncogene · doi:10.1038/onc.2016.350 · Cited by 53
Role of Mdm4 in drug sensitivity of breast cancer cells
Lam, S., Lodder, K., Teunisse, A. F. A. S., Rabelink, M. J. W. E., Schutte, M., & Jochemsen, A. G. (2010) · Oncogene · doi:10.1038/onc.2009.522 · Cited by 52
Targeting the ubiquitin–proteasome system to activate wild-type p53 for cancer therapy
Allende-Vega, N., & Saville, M. K. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.004 · Cited by 52
Ubiquitylation of p53 by the APC/C inhibitor Trim39
Zhang, L., Huang, N.-J., Chen, C., Tang, W., & Kornbluth, S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212047110 · Cited by 51
Rinaldo, C., Prodosmo, A., Siepi, F., Moncada, A., Sacchi, A., Selivanova, G., & Soddu, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0337 · Cited by 51
Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
Maerken, T. V., Rihani, A., Goethem, A. V., Paepe, A. D., Speleman, F., & Vandesompele, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.11.002 · Cited by 51
Gao, C., Xiao, G., Piersigilli, A., Gou, J., Ogunwobi, O. O., & Bargonetti, J. (2019) · Breast Cancer Research · doi:10.1186/s13058-018-1094-8 · Cited by 50
Chen, J., Wang, J., Zhang, Q., Chen, K., & Zhu, W. (2015) · Scientific Reports · doi:10.1038/srep17421 · Cited by 50
Self-citationMDM4 (MDMX) and its Transcript Variants
Mancini, F., Conza, G. D., & Moretti, F. (2009) · Current Genomics · doi:10.2174/138920209787581280 · Cited by 49
Wu, W., Xu, C., Ling, X., Fan, C., Buckley, B., Chernov, M. V., Ellis, L., Li, F., Muñoz, I. G., & Wang, X. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.358 · Cited by 49
BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death
Wade, M., Rodewald, L. W., Espinosa, J. M., & Wahl, G. M. (2008) · Cell Cycle · doi:10.4161/cc.7.13.6072 · Cited by 48
Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma
Ohnstad, H. O., Castro, R., Sun, J., Heintz, K., Vassilev, L. T., Bjerkehagen, B., Kresse, S. H., Meza‐Zepeda, L. A., & Myklebost, O. (2013) · Cancer · doi:10.1002/cncr.27837 · Cited by 42
Han, X., Garcia‐Manero, G., McDonnell, T. J., Lozano, G., Medeiros, L. J., Xiao, L., Rosner, G. L., Nguyen, M. H., Fernandez, M., Valentin-Vega, Y. A., et al. (2006) · Modern Pathology · doi:10.1038/modpathol.3800727 · Cited by 48
Computational Modeling as a Tool to Investigate PPI: From Drug Design to Tissue Engineering
Pérez, J. J., Pérez, R. A., & Pérez, A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.681617 · Cited by 48
Li, Q., Li, G., Li, P., Wang, H., Fang, X., He, T., & Li, J. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101155 · Cited by 47
Metadata
- Authors
- Hu, B., Gilkes, D. M., Farooqi, B., Sebti, S. M., & Chen, J.
- Affiliations
- Moffitt Cancer Center (US)
- Corresponding author
- Chen, Jiandong
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-11
- Volume
- 281
- Issue
- 44
- Pages
- 33030-33035
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2052516738
- Cited by
- 236
- References
- 29
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 5 · 2023: 6 · 2022: 4 · 2021: 10 · 2020: 10 · 2019: 10 · 2018: 10 · 2017: 7 · 2016: 17 · 2015: 5 · 2014: 11 · 2013: 14 · 2012: 17
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5082 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- MDMX, MDM2, p53 activation, Nutlin-3, MDM2 inhibitors, p53 stabilization, tumor suppressor, siRNA knockdown, growth arrest
- MeSH terms
- Cell Line, Humans, Imidazoles, Piperazines, Protein Binding, Tumor Suppressor Protein p53, RNA, Small Interfering, Cell Proliferation, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.